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Community Pharmacists Experience of Pregabalin Abuse and Misuse: A 1 
Quantitative Study from Jordan 2 
 3 
Abstract 4 
Pregabalin is an anticonvulsant that has an abuse potential. The aim of this study was to 5 
investigate abuse/misuse of pregabalin in Jordan from the perspective of community 6 
pharmacists. A cross-sectional survey using a structured questionnaire was delivered to a 7 
sample of community pharmacies. Self-reported method was used to fill the surveys. A 8 
total of 151/205 questionnaires were completed (response rate = 74.1%). A total of 132 9 
respondents (87.4%) reported cases of pregabalin abuse in their pharmacies. Less than half 10 
of the respondents (n = 69; 45.7%) indicated that pregabalin requests were, in most of the 11 
cases, not accompanied by prescriptions. More than half of the sample (55.8%) noticed an 12 
increased pattern of pregabalin abuse/misuse during the last six months. The study 13 
underscored the need for regulatory efforts and pharmacovigilance to manage pregabalin 14 
abuse, along with a pharmacist and patient education at a community pharmacy level. 15 
 16 
 17 
 18 
Keywords: Abuse, Communiy Pharmacy, Jordan, Pregabalin, Survey 19 
 20 
 21 
 22 
 23 
2 
 
Introduction 24 
Abuse and misuse of prescription drugs are reported to be a global problem (Lessenger & 25 
Feinberg, 2008). Misuse of prescription drugs is defined by the National Institute on Drug 26 
Abuse (NIDA) as taking a medication in a manner or dose other than prescribed; taking 27 
someone else’s prescription, even if for a legitimate medical complaint such as pain, or 28 
taking a medication to feel euphoria (i.e., to get high). The latter definition is what is 29 
described sometimes in the literature as drug abuse (Hughes et al., 1999; Wazaify et al., 30 
2006). While the updated definition of misuse of non prescription medicine (NPM) is to be 31 
used for a legitimate medical purpose, but in an incorrect manner either in terms of dose or 32 
duration (Wazaify et al., 2016). Abuse of NPM was defined as the use for a non-medical 33 
purpose, e.g. to achieve mind-altering effects or weight loss (Fingleton et al., 2016). NPMs 34 
misuse and abuse have increased lately, especially with the self-care revolution, the increasing 35 
number and access to medicines and the wide availability of online health information (Wright 36 
et al., 2015). By definition, any prescription or non-prescription drug can be misused, but 37 
only specific products can be abused as follows. (Fingelton et al., 2016). The most 38 
commonly reported prescription medications to be abused worldwide are stimulants such 39 
as methylphenidate and central nervous system (CNS) depressants such as sedatives (e.g. 40 
benzodiazepines, opioids, or pregabalin (Loftus & Wright, 2014; (NIDA, 2014). 41 
 42 
Pregabalin is an analogue of the gamma-aminobutyric acid (GABA) mammalian 43 
neurotransmitter and its structurally related compound; gabapentin. They act as inhibitory 44 
modulators of neuronal excitability that reduce ectopic neuronal activation of hyperexcited 45 
neurons while normal activation remains unaffected (Papazisis & Tzachanis, 2014). 46 
Pregabalin is approved for the treatment of partial epilepsy; generalized anxiety disorder; 47 
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peripheral and central neuropathic pain and fibromyalgia with an accepted dosage range of 48 
150 mg to 600 mg/day (Papazisis & Tzachanis, 2014). The reported euphoria that occurs 49 
as an adverse event in up to 10% of patients is the main cause that would lead contributes 50 
to abuse (Schwan et al., 2010). 51 
 52 
A study conducted in Germany revealed that 12.1% of urine specimens that had been 53 
collected from addicts to heroin and other substances, tested positive for pregabalin without 54 
medical purpose for its use (Grosshans, et al., 2013). Another study conducted in the UK  55 
suggested that patients at high risk of addiction were prescribed higher than the 56 
recommended dose of pregabalin. Pregabalin and gabapentin were used alongside opiates 57 
to potentiate their effects. Also they can be used alone in higher than recommended doses 58 
concluded that the This study  So, the authorto produce sedation and psychedelic effects. 59 
quantities supplied should be limited because of the possibility of misuse (Loftus and 60 
Wright, 2014).  61 
 62 
In Jordan, like other countries in the region, with the exception of controlled drugs (e.g. 63 
opioids and some benzodiazepines), almost any medicine can be bought from the 64 
community pharmacy without a prescription (Wazaify & Scott, 2017). The Jordan Food 65 
and Drug Administration (JFDA) is the legislative body that classifies medications into 66 
prescription and Over-The-Counter (OTC) drugs. However, in many cases, this legislation 67 
is not strictly enforced (Wazaify and Albsoul-Younes, 2005). This a Availability linked 68 
with the affordability and perception of safety of such products by the general public 69 
(Wazaify et al., 2008), may lead to the abuse of more and different kinds of nonprescription 70 
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OTC and prescription drugs (Albsoul-Younes et al., 2010). A study conducted in Jordan in 71 
2014 highlighted the changes that may have happened in relating to this problem during 72 
the previous 10 years. The study showed the retraction of some products’ suspected of 73 
abuse (e.g. misoprostol). On the other hand, New products have additionally appeared on 74 
the new list, such as the anticonvulsant, Lyrica® (Pregabalin) and certain specific 75 
ophthalmic drops with sympathetic, antihistamine or anticholinergics properties (e.g. 76 
cyclopentolate, Wazaify et al., 2016). This resulted in the addition inclusion of pregabalin 77 
containing products to a list of restricted drugs where use that requires a medical 78 
prescription. but was not competent to be under scheduled controlled drugs (JFDA, 2014). 79 
In addition, it prohibited the supply of samples of drugs containing this substance or 80 
granting quantities of incentives on the quantities sold of medicines (Jordan Food and 81 
Drugs Administration, 2017a).  82 
According to the Jordanian Drug and Pharmacy Practice Law (2013), opioids, opioid 83 
derivatives, or opioid containing preparations are controlled as Schedules 1–8 drugs. The 84 
pharmacist is required to keep a record of these special prescriptions and supply against 85 
them, for JFDA inspection. As such, a pharmacist will be subject to prosecution if found 86 
to be selling Schedules 1–8 products (Jordan Food and Drug Administration, 2017b). 87 
However, some prescription-only-medicines that are liable for abuse are not scheduled yet 88 
in many Middle Eastern countries (e.g. pregabalin (At the time this study was conducted), 89 
performance enhancing hormones, some anticholinergic drugs).This aborts the chance to 90 
trace any violation and allows some pharmacists to sell such preparations without a 91 
prescription. (Wazaify & Scott, 2017).  92 
 93 
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Scheduling of pregabalin was documented in 2005 in the USA as schedule V of the 94 
Controlled Substances Act (CSA; Drug Enforcement Administration, Department of 95 
Justice, 2005). In Jordan, pregabalin has been scheduled to be controlled as schedule III 96 
controlled drug on since December 7th, 2017,  (Jordan Food and Drug Administratiuon, 97 
2017c). This study came was conducted prior to the scheduling of the drug in Jordan and 98 
aimed to investigate the experience of community pharmacists regarding the abuse and 99 
misuse of pregabalin products in their practice setting.   100 
 101 
Materials and Methods 102 
Study design, setting and subjects 103 
This is a cross-sectional quantitative study that was conducted in Amman- Jordan between 104 
November 2016 and January 2017 to evaluate the experience of community pharmacists’ 105 
regarding pregabalin products abuse and misuse. During the study period, 205 pharmacists 106 
and pharmacy assistants were approached in different community pharmacies (independent 107 
or chain) located in different regions in Amman, the capital of Jordan. They were asked to 108 
participate in this study by filling a prevalidated, prepiloted questionnairebelow). Drop and 109 
Pick technique was used in this part of the study to collect the data from pharmacies as 110 
explained below. 111 
Study questionnaire and data collection 112 
A previously validated and tested questionnaire was used in this study. The questionnaire 113 
was based originally on that used by Hughes et al. (1999). However, in order to be able to 114 
use it in Jordan the questionnaire was translated to Arabic and then back-translated to 115 
English in order to assure validity. Every effort was made during the review of literature 116 
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review to ensure content validity. Moreover, various drafts of the questionnaire were 117 
evaluated individually by three senior academics who were PhD holders (Pharmacy 118 
Practice, Public Health Policy and a Statistician) in order to ensure face validity. The final 119 
version of the questionnaire was then distributed using drop and pick technique. Self-120 
reported method was used to fill out the questionnaire. In this approach, the study 121 
researcher first author (A.A) went to different community pharmacies and handed the 122 
questionnaire personally to all pharmacists available in the shift. The completed surveys 123 
were picked up at a later time. The questionnaire was anonymous and consisted of two 124 
sections: 125 
Section One 126 
Limited demographic details were collected, so as to protect pharmacists’ anonymity. 127 
Participants were requested to state only the name of their area where their pharmacy was 128 
located and to allocate it as being on a main road, a side street, or in a mall. Finally, 129 
pharmacists were asked to state their gender and years of experience in the profession. 130 
 Section Two  131 
Section two included the following points: 132 
 Pharmacists’ awareness regarding pregabalin liability for abuse and main side effects 133 
 Pharmacists’ experiences with customers suspected of abusing the drug and what the 134 
signs that led the pharmacists and the researchers to suspect them, for example (the 135 
pattern and repeated requests, pharmacists’ familiarity with patients and the quantity 136 
requested).  137 
 Reporting of any pregabalin drug they had suspected in the past six months of being 138 
abused, and if they noticed the request trends were changing. The main pregabalian 139 
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products available in the Jordanian market at the time of study were: Lyrica®, Zega®, 140 
Galica®, Regab® , Epigab® and Neogaba® 141 
 Description of suspected cases of abuse in their own pharmacies (if any), and a profile 142 
of the typical abuser of each product identified.  143 
 Maximum number of packs that they had been requested to sell and which they 144 
suspected of being abused, and whether the patients who purchased (or attempted to 145 
purchase) these products were regular or new customers. 146 
 Information on any strategies the pharmacists had in place to limit suspected abusers’ 147 
access to the products. 148 
 149 
Statistical analysis 150 
The data of the completed questionnaire were coded and entered into SPSS software-151 
version 22 for analysis. Descriptive analysis was conducted and frequency distributions 152 
were collected for responses to all questions. Chi square and Fisher exact tests were used 153 
to detect significant relationship between variables. A p-value less than 0.05 was 154 
considered significant throughout the analysis.  155 
 156 
Results 157 
Demographic details of participating community pharmacy staff and pharmacies  158 
A total of 152 out of the 205 distributed questionnaires (response rate= 74.1%) were 159 
returned. Questionnaires were filled by community pharmacists and pharmacy assistants 160 
at different independent and chain pharmacies in Amman (N=90). One questionnaire was 161 
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excluded due to missing data, which ended up with a total of 151 questionnaires to be 162 
analyzed. 163 
 164 
The majority of respondent pharmacists (n=95, 62.9%) were between 20 and 30 years of 165 
age and had a Bachelor of Pharmacy or Pharm. D degrees (n = 132; 87.4%). More than 166 
half of participating pharmacists were female (n = 89, 58.9%) and almost one-third of the 167 
pharmacists had up to one year of experience (n = 49, 32.5%). The majority of participating 168 
staff (n = 98, 64.9%) reported that they would not receive bonus if they had not achieved 169 
a target sale of products. Also, the majority of participating pharmacies were independent 170 
(n = 64, 71.1%), and located on a main road (n = 62, 68.9%). More than third of 171 
participating pharmacists (n=53, 35.1%) reported having incentive offers on pregabalin 172 
sales from medication stores.  A summary of participating pharmacies and staff is provided 173 
in Table 1. 174 
Insert Table 1 about here 175 
 176 
Pregabalin products suspected of abuse and misuse  177 
The majority of respondents (n= 132, 87.4%) suspected pregabalin product abuse/misuse 178 
in community pharmacies. Almost half of respondents indicated that pregabalin requests 179 
they had received were not accompanied by a prescription in most of the cases (n = 69, 180 
45.7%). Most of the participated pharmacists (n=203/364, 55.8%) noticed an increased 181 
pattern of abuse/misuse with time as described in Figure 1. 182 
Insert Figure 1 about here 183 
 184 
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Among pregabalin products, Lyrica® was the most frequently reported to be suspected of 185 
abuse (n=100 , 25.4%).  It was reported to be mostly abused by male customers whose age 186 
ranged between 26-50 years, followed by Galica® and Zega® (n=84, 21.4%), and (n=81, 187 
20.6%) respectively. Regarding most commonly abused strengths, 75 mg was reported to 188 
be the most frequently requested strength in community pharmacies (n=181, 46.05%). This 189 
was mainly by males whose age ranged between 26-50 years, followed by 150 mg (n=144, 190 
36.6%). Table 3 2 details the most frequently reported pregabalin products to be suspected 191 
of abuse/misuse by community pharmacists in Jordan. 192 
 193 
Insert Table 2 about here 194 
 195 
Pharmacists’ methods to limit customers’ access to pregabalin products  196 
Pharmacists employed several methods to limit customers’ access to products they had 197 
suspected of being abused. The two most commonly used methods, as stated by 198 
pharmacists, were insisting to have a valid prescription to dispense the product (n = 81; 199 
54.4%) and refusing the sale and/or of stating that the product was not available (n = 70; 200 
47%). Only 7 (4.7%) pharmacists reported that they had not acted on the problem and they 201 
had simply sold the requested products. These pharmacists all were all younger than 40 202 
years of age (p = 0.636). Pharmacists with 1–5 or 6–10 years of experience had no 203 
statistically significant difference in refusing to sell the product and/or insisting to have a 204 
prescription to dispense the product (35.8% and 24.7%, respectively; p = 0.386) compared 205 
to those with less experience (16%). Also, there was no statistically significant difference 206 
in sale refusal/or insisting to have a prescription between pharmacists and pharmacy 207 
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assistants (88.9% vs. 11.1%; p = 0.692) or between pharmacy staff working in independent 208 
and chain pharmacies (61.7% vs. 38.3%; p = 0.803). More staff working in independent 209 
pharmacies (71.4%) than those working in chain pharmacies (28.6%) reported that they 210 
simply sold the requested pregabalin products just like any other product. Yet, this 211 
diffference was not statistically significant (p>0.05). Methods used to limit access to 212 
pregabalin were also not associated with gender of the pharmacists (p > 0.05). Details of 213 
the reported methods used by pharmacy staff to deal with suspected pregabalin abuse are 214 
summarized in Table 3. 215 
 216 
Insert Table 3 about here 217 
 218 
The largest amount of commonly abused pregabalin products requested simultaneously by 219 
a customer ranged between 1 and 50 packs (mean = 3.24± 5.3). In 81.9% (n = 91) of 220 
suspected customer requests, the pharmacist refused to sell the product, either by claiming 221 
that the product was not available (n = 42; 37.8%) or by insisting on having a prescription 222 
to receive the product (n = 49; 44.1%). Only 15 pharmacists (13.5%) reported selling the 223 
exact requested amount and five (4.5%) reported selling a smaller amount than that 224 
requested. 225 
 226 
Pharmacy staff perspective regarding pregabalin requests  227 
The majority of pharmacists (n=120, 81.6%) reported that most of the customers requesting 228 
these products were new customers to their pharmacy compared to 18.4% reported most 229 
requests by regular customers (n=27). During the study, more than half (n=78, 52.7%) of 230 
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the responding pharmacy staff noticed a difference in requesting pregabalin after the 231 
announcement to restrict amount of sale by Jordan Food and Drug Administration (JFDA) 232 
in 2014. On the other hand, a little less proportion (n= 70; 47.3%) noticed that there had 233 
been no difference in drug requests.  234 
 235 
Discussion 236 
This study highlighted community pharmacists’ experiences regarding the suspected 237 
abuse/misuse of pregabalin in their practice setting. To the best of authors’ knowledge, this 238 
is the first study in the literature to explore the problem of pregabalin abuse/misuse from 239 
community pharmacists’ perspective. A previous study conducted in Jordan investigated 240 
the abuse/misuse of all drugs sold with or without a prescription in community pharmacies 241 
highlighted the emergence of new drugs on the list of suspected drugs of abuse such as: 242 
ophthalmic drops and pregabalin (Wazaify et al., 2016).  This may be due to the re-243 
scheduling of some of the most common drugs of abuse in 2013 (e.g. Alprazolam) from 244 
'prescription-only-status' to become controlled as schedule III drugs (Jordan Food and 245 
Drug Administration, 2014). In other words, the restriction on commonly abused drugs, 246 
has possibly led to some people looking for a legal and available alternative (Wazaify and 247 
Scott, 2017). The fact that We speculate that this has resulted in more reported cases of 248 
abuse of pregabalin products in community pharmacies.  249 
 250 
At the time this study was conducted, pregabalin was classified as a prescription only 251 
medicine that did require a prescription to be dispensed. However, the Pharmacy and Drug 252 
law does not require pharmacists to keep records of these prescriptions (Jordanian Food 253 
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and Drugs Administration, 2017d; unlike the scheduled products described above), thus 254 
making it difficult for regulators to trace violations and facilitating the pharmacists to 255 
illicitly sell such preparations without a prescription (Wazaify & Scott, 2017). This practice 256 
(i.e. selling prescription-only products without a prescription) has also been noted in other 257 
Arab countries like Egypt (Jousilahti et al., 1997), Kuwait (Matowe et al., 2003), and 258 
Palestine (Sweileh et al., 2004). 259 
 260 
It is only after a series of studies that looked into this problem (Schwan et al., 2010; Millar 261 
et al., 2013; Al-Husseini et al., 2017a) from different angles, that pregabalin has been 262 
controlled in Jordan to be schedule III drug. (JFDA, 2017c). Since community pharmacists 263 
are the most acccessible health care professionals and the first defence line against abuse 264 
of prescription and non-prescription products (Dole & Tommasello, 2002), it is believed 265 
that the scheduling the drug and the consequent tightening of inspection on its sale in 266 
community pharmacies would limit this problem. Another point worth mentioning, We 267 
equally recognise howver that the restriction and scheduling of prescription drugs may 268 
limit acccess of genuine patients who need the drug for different ligitimate indications (e.g. 269 
neuropathy). The effect of such scheduling will only be revealed through further research 270 
in the coming few years that follow the scheduling.  271 
 272 
More than half of the pharmacists in our sample, confirmed that they had received 273 
suspicious requests for pregabalin products, during the past six months, most of which was 274 
the brand name Lyrica® and with a strength of 75 mg. In contrast to the observational part 275 
of the study, *(Al-Husseini et al., 2018) the generic name Zega® and the concentration 150 276 
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mg were the most pregabalin products requested by self-medication method (Al-Husseini 277 
et al, 2017b). This may be due to the fact that pharmacists in general believe that the 278 
original brands are of higher quality and to be are more effective than the generic products 279 
(Grover et al., 2011). Moreover, the original brand name is sometimes used as a substitute 280 
for the less common generic name among people (e.g. Panadol vs. Paracetamol). Male 281 
gender was the most commonly suspected of pregabalin abuse, in this study. This is similar 282 
to different studies in the literature considering male sex as a risk factor to addictive 283 
behaviour (Gahr et al., 2013; Gahr et al., 2014).   284 
 285 
Another point worth mentioning is that some pharmacists reported that one of the main 286 
reasons of increased pregabalin abuse recently was the incentive offers from medication 287 
stores. This was believed to put pressure on the responsible pharmacist to buy and sell large 288 
quantities of the drug to get such incentives. So it led the JFDA in 2017 to release an 289 
announcement not to grant quantities of incentives on the quantities sold of medicines 290 
containing pregabalin (Jordanian Food and Drugs Administration, 2017b).  291 
 292 
Being classified as a prescription only medicine does not allow the pharmacist to dispense 293 
the drug by him/herself without a prescription written by a physician, this is where the 294 
professional and ethical judgement of the pharmacist is important. Where pharmacists need 295 
to differentiate between being "ethical" and being "legal" as both terms, although relevant, 296 
are definitely not interchangeable. Some pharmacists may respond and sell the requested 297 
large amounts of products because they perceive this as being 'legal' since this drug is not 298 
“scheduled”. Moreover, 13.1 % of final year pharmacy students either disagreed/strongly 299 
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disagreed or were unsure that it was unethical to sell controlled drugs to suspected 300 
misusers/abusers (Jaber et al., 2015). Thus, it is suggested that more focus should be 301 
stressed on the teaching and practice of ethics to pharmacy graduates (Wazaify et al., 2010).   302 
 303 
The methods employed by Jordanian pharmacists to limit the supply of pregabalin products 304 
liable for abuse did not differ from those reported by pharmacists in other countries (Ball 305 
& Wild, 1989; Paxton & Chapple, 1996; Hughes et al., 1999). Traditional methods used 306 
by pharmacists have included refusal of sale of such products or keeping them out of sight 307 
and/or requesting a medical prescription (Paxton and Chapple, 1996; Hughes et al., 1999; 308 
Albsoul-Younes et al., 2010; Wazaify et al., 2016). These methods are of limited value as 309 
patients may seek a supply from another pharmacies or what is known as “pharmacy-310 
hopping” (Van Hout, 2014). This problem could be minimized if pharmacists networked 311 
more frequently with one another where a suspected abuser would be reported to other 312 
pharmacies of the locality.  A better and more comprehensive system is connecting all 313 
pharmacies electronically on a national level to report about drugs of potential abuse 314 
(Manchikanti et al., 2005). Moreover, an interventional harm minimization model to 315 
identify and refer those at risk of prescription or nonprescription drug abuse could be 316 
implemenetd in community pharmacies (Wazaify et al., 2006). Such model requires 317 
training of community pharmacists and more collaborative work with physicians and 318 
community addiction teams.  319 
 320 
Limitations of the Study 321 
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This part of the study had been limited by the following: 1) the author’s delivered the 322 
questionnaires to respondents by hand. Although the success of this strategy was reflected 323 
in the high response rate (74.1%), it also could have affected the anonymity of the 324 
questionnaire and subsequently whether the pharmacy staff felt comfortable to freely report 325 
their experience. We recommend that future studies use social media or specialized internet 326 
pharmacists for these kinds of studies; 2) the data in this study were based on pharmacists’ 327 
and pharmacy assistants’ perceptions of day-to-day events, which was highly subjective 328 
and represented only a single point of view. A direct observational pharmacy-based study 329 
(which was already conducted, Alhusseini et al., 2017) was considered more dependable 330 
in this regard; 3) the questionnaire was filled by pharmacy personnel in community 331 
pharmacies in Amman, the capital of Jordan, which is not representative of the whole 332 
Jordan. It is recommended that future studies involve a larger number of community 333 
pharmacies in different regions all over Jordan.  334 
 335 
Conclusion 336 
The majority of participating pharmacists had reported that pregabalin had the potential to 337 
be abused, with most of suspected pregabalin abusers were male aged between 26 to 50 338 
years old and from moderate socioeconomic class. In addition,  most of the pregabalin 339 
requests were not accompanied by a prescription and were noticed to be increased during 340 
the past six months. All these findings call the attention for implementation of effective 341 
community pharmacy based interventions to raise patient, neurologists and pharmacists 342 
awareness regarding pregabalin potential for abuse and ultimately restrict prescribing and 343 
or dispensing on this product to only those in medical need.   344 
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